Ten-year Survival of Corpus Uteri Cancer Patients in Urban Communities of Three Cities in Liaoning Province
10.3971/j.issn.1000-8578.2021.21.0474
- VernacularTitle:辽宁省三城市社区居民子宫体癌10年生存率分析
- Author:
Shuang LI
1
;
Xiaoxia AN
;
Xun LI
;
Weiwei ZHANG
;
Guowei PAN
;
Huijuan MU
Author Information
1. Department of Non-communicable Disease Prevention and Control, Liaoning Provincial Center for Disease Prevention and Control, Shenyang 110005, China
- Publication Type:Research Article
- Keywords:
Corpus uteri cancer;
Survival rate;
Diagnosis stage;
Treatment;
Histology
- From:
Cancer Research on Prevention and Treatment
2021;48(12):1113-1117
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze 10 years survival status of urban female patients with corpus uteri cancer and its influencing factors in Liaoning Province. Methods Based on Liaoning cancer register database, 426 patients with corpus uteri cancer in Shenyang, Anshan and Benxi from 2000 to 2002 were randomly selected. They were followed up passively and actively. Life table method and Ederer Ⅱ method were used to calculate the observed survival rate (OSR), the expected survival rate (ESR) and the relative survival rate (RSR). Results We finally included 218 corpus uteri patients. The diagnosis proportions of stage Ⅰ-Ⅳ were 59.2%, 11.5%, 11.0% and 8.7%, respectively. Ten-year RSR and OSR were 59.6% and 67.9%. The diagnosis stage was negatively correlated with 10-year RSR. The 10-year RSR of patients treated with surgery was 71.3%, which was 6.6 times that of non-surgical treatment (10.8%). The 1-year RSR to 10-year RSR ranged from 88.4% to 67.5%. The RSR of each stage was Ⅰ-Ⅱ(95.7%-77.9%) > Ⅲ (71.4%-44.5%) > Ⅳ (58.4%-11.0%). Multivariate Cox model analysis showed that age > 55 years old, late diagnosis stage and non-surgical treatment were the main factors affecting the 10-year survival rate. Conclusion Early diagnosis and surgical treatment can significantly improve the long-term survival rate of patients. Therefore, we should strengthen the early detection and treatment of corpus uteri cancer, standardize and strengthen the screening program.
